No Prescription |
 |
 | ||
|
Tenoric Tenoretic |
|
| ||
No Prescription » Prescription Drugs 15 » Tenoric Tenoretic Tenoretic (atenolol-chlorthalidone) is a fixed-dose combination of the beta-blocker atenolol and the diuretic chlorthalidone for hypertension. Tenoretic is used to treat high blood pressure. Buy Tenoric Tenoretic and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Tenoric Tenoretic: Product Type: Prescription Drugs 15 Tenoric (Tenoretic Generic Atenolol & Chlorthalidone) Tenoric (Tenoretic Generic Atenolol & Chlorthalidone) Tenoretic Generic Atenolol & Chlorthalidone 100/25mg 100 Tablets 100/25mg 400(4 x 100) Tablets 100/25mg 200(2 x 100) Tablets 50/12.5mg 200(2 x 100) Tablets 50/12.5mg 100 Tablets 50/12.5mg 400(4 x 100) Tablets Tenoretic Generic Atenolol & Chlorthalidone Tenoric
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
